re information, please visitHome - Ferring Japan

*As of September 2025, within Japan.

References

1Inoue K, Kikuchi E, Nishiyama H, Nasu Y,et al. Efficacy and Safety of Nadofaragene Firadenovec for BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer: Initial Results From an Ongoing Japanese Phase 3 Trial. Presented at the 112 Annual Meeting of the Japanese Urological Association, April 19, 2025. Available at:https://www.micenavi.jp/jua2025/search/detail_program/id:2055
2Moyer J, Durant A, Nguyen M. Real-world outcomes of nadofaragene firadenovec in BCG-unresponsive non-muscle invasive bladder cancer. Presented at the Annual Meeting of the American Society of Clinical Oncology GU, February 2025.
3Narayan VM,et al. Efficacy of Intravesical Nadofaragene Firadenovec for Patients with BCG-Unresponsive Non-muscle Invasive Bladder Cancer: 5 Year Follow-Up from a Phase 3 Trial. J Urol. 2024 May 5. doi: 10.1097/JU.0000000000004020.
4World Cancer
=*=*=*=*=*=
当前为第9/10页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页